The Cancer Letter

Inside information on cancer research and drug development

So you want to be a cancer center director…

AACI sees nearly one-in -four turnover in 12 months among directors at top academic cancer centers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The caveats should be acknowledged:

Yes, all cancer centers are different. If you’ve seen one, you’ve seen one. Yes, every center director has a different political and economic situation on his or her hands, and, sure, the observation that follows in the next paragraph could well be a fluke:

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

AACR progress report highlights AI’s role in research and clinical care
Obstacles to progress include systemic disparities and dwindling appropriations

Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report. 
By McKenzie Prillaman
Byline
Paul Goldberg
Editor & Publisher
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account